Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide, though with limited success. This analysis evaluated the efficacy of eluxadoline in patients previously treated with loperamide in two phase 3 studies. METHODS: Adults with IBS-D (Rome III criteria) were enrolled and randomized to placebo or eluxadoline (75 or 100 mg) twice daily for 26 (IBS-3002) or 52 (IBS-3001) weeks. Patients reported loperamide use over the previous year and recorded their rescue loperamide use during the studies. The primary efficacy end point was the proportion of patients with a composite response of simultaneous improvement in abdominal pain and reduction in diarrhea. RESULTS: A total of 2,428 patients were enrolled; 36.0% reported prior loperamide use, of whom 61.8% reported prior inadequate IBS-D symptom control with loperamide. Among patients with prior loperamide use, a greater proportion treated with eluxadoline (75 and 100 mg) were composite responders vs. those treated with placebo with inadequate prior symptom control, over weeks 1-12 (26.3% (P=0.001) and 27.0% (P<0.001) vs. 12.7%, respectively); similar results were observed over weeks 1-26. When daily rescue loperamide use was imputed as a nonresponse day, the composite responder rate was still higher in patients receiving eluxadoline (75 and 100 mg) vs. placebo over weeks 1-12 (P<0.001) and weeks 1-26 (P<0.001). Adverse events included nausea and abdominal pain. CONCLUSIONS: Eluxadoline effectively and safely treats IBS-D symptoms of abdominal pain and diarrhea in patients who self-report either adequate or inadequate control of their symptoms with prior loperamide treatment, with comparable efficacy and safety irrespective of the use of loperamide as a rescue medication during eluxadoline treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationThe impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334
Self-citationThe Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future
Hulisz, D. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.4.299 · Cited by 215
Irritable bowel syndrome: Physicians' awareness and patients' experience
Olafsdottir, L. B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i28.3715 · Cited by 41
Research works printed but not linked: 11
- Longstreth, 2006, Functional bowel disorders., Gastroenterology, 130, 1480, 10.1053/j.gastro.2005.11.061 · DOI · Paper page
- Chey, 2015, Irritable bowel syndrome: a clinical review., JAMA, 313, 949, 10.1001/jama.2015.0954 · DOI · Paper page
- Pare, 2006, Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study., Clin Ther, 28, 1726, 10.1016/j.clinthera.2006.10.010 · DOI · Paper page
- Drossman, 2016, Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV., Gastroenterology, 150, 1262, 10.1053/j.gastro.2016.02.032 · DOI · Paper page
- Ruppin, 1987, Review: loperamide-a potent antidiarrhoeal drug with actions along the alimentary tract., Aliment Pharmacol Ther, 1, 179, 10.1111/j.1365-2036.1987.tb00617.x · doi:10.1111/j.1365-2036.1987.tb00617.x
- Chang, 2014, American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome., Gastroenterology, 147, 1149, 10.1053/j.gastro.2014.09.002 · DOI
- Cann, 1984, Role of loperamide and placebo in management of irritable bowel syndrome (IBS)., Dig Dis Sci, 29, 239, 10.1007/BF01296258 · DOI · Paper page
- Wade, 2012, Modulation of gastrointestinal function by MuDelta, a mixed opioid receptor agonist opioid receptor antagonist., Br J Pharmacol, 167, 1111, 10.1111/j.1476-5381.2012.02068.x · DOI · Paper page
- Hovdenak, 1987, Loperamide treatment of the irritable bowel syndrome., Scand J Gastroenterol Suppl, 130, 81, 10.3109/00365528709091004 · DOI · Paper page
- Efskind, 1996, A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome., Scand J Gastroenterol, 31, 463, 10.3109/00365529609006766 · DOI · Paper page
- Lavo, 1987, Loperamide in treatment of irritable bowel syndromea double-blind placebo controlled study., Scand J Gastroenterol, 22, 77, 10.3109/00365528709091003 · DOI · Paper page
Cited by
ACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Self-citationBlack, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Savarino, E., Zingone, F., Barberio, B., Marasco, G., Akyuz, F., Akpinar, H., Barboi, O., Bodini, G., Bor, S., Chiarioni, G., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12259 · Cited by 146
Brenner, D. M., & Sayuk, G. S. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01116-z · Cited by 55
Kemppinen, A., Howell, C., Allgar, V., Dodd, M., Gregson, J., Knowles, C., McLaughlin, J., Pandya, P., Whorwell, P., Markaryan, E., et al. (2020) · Trials · doi:10.1186/s13063-020-4069-x · Cited by 14
Metadata
- Authors
- Lacy, B. E., Chey, W. D., Cash, B. D., Lembo, A. J., Dove, L. S., & Covington, P. S.
- Venue
- American Journal of Gastroenterology
- Published
- 2017-06
- Volume
- 112
- Issue
- 6
- Pages
- 924-932
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2605950827
- Cited by
- 54
- References
- 6
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.